Potentials for the combined therapy of urination disorders in men: the choice of optimal scheme of treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Moderate to severe urination disorders occur in 13-29% of men, and their frequency increases progressively with age. The key for successful use of the capabilities of modern drug therapy is the understanding of the pathophysiological bases of urination disorders. Despite some successes of monotherapy with а- adrenoblockers and 5

Full Text

Restricted Access

References

  1. Seftel A.D., de la Rosette J., Birt J. et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int. J Clin. Pract. 2013;67(1):32-33.
  2. Emberton M., Cornel E.B., Bassi P.F. et al. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int. J Clin. Pract. 2008; 62:1076-1086.
  3. Smith A.B., Carson C.C. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther. Clin. Risk Manag. 2009,5:535-545.
  4. Lepor H. The evolution of alphq-blockers for the treatment of benign prostatic hyperplasia. Rev. Urol. 2006; 8 (Suppl. 4): S3—S9.
  5. Montorsi F., Alcaraz A, Desgrandchamps F. et al. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefis. Prostate. 2009;69:895-907.
  6. Gilling P., Jacobi G., Tammela T. et al. Efficacy of dutasteride and Wnasteride for the treatment of benign prostate hyperplasia: results of the 1-year Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2005; 95(Suppl. 1):1—38 abstract U051.
  7. McConnell J.D., Roehrborn C.G., Bautista O.M. et al. The long-term effect of doxazosin, Wnasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl. J Med. 2003;349:2387-2398.
  8. Roehrborn C.G., Siami P., Barkin J. et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179:616-621.
  9. Roehrborn C.G., Siami P., Barkin J. et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 2010; 57(1):123-131.
  10. Montorsi F., Roehrborn C., Garcia-Penit J. et al. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU Int. 2011;107(9):1426—1431.
  11. McConnell J.D., Bruskewitz R., Walsh P. et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl. J Med. 1998;338:557-563.
  12. Kaplan S.A., McConnell J.D., Roehrborn C.G. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group et al. Combination therapy with doxazosin and Finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006;175:217-220.
  13. Roehrborn C.G., Siami P., Barkin J. et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 2010; 57(1):123-131.
  14. Logan Y.T., Belgeri M.T. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. Am. J Geriatr. Pharmacother. 2005;3:103-114.
  15. Barkin J., Guimarães M., Jacobi G. et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur. Urol. 2003; 44:461-466.
  16. Nickel J.C., Barkin J., Koch C. et al. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can. Urol. Assoc. J. 2008;2:16-21.
  17. McNaughton-Collins M., Barry M.J. Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Am. J Med. 2005;118(12):1331-1339.
  18. Chapple C.R., Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract in men: focus on the bladder. Eur. Urol. 2006;49:651-659.
  19. Abdel-Aziz K.F., Lemack G.E. Overactive bladder, outlet, or both? Curr. Urol. Rep. 2002;3:445-451.
  20. Abrams P., Kaplan S.A., De Koning Gans H.J. et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175: 999-1004.
  21. Roehborn C.G., Abrams P., Rovner E.S. et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006;97:1003-1006.
  22. Chapple C., Herscham S., Abrams P. et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur. Urol. 2009; 56:534-541.
  23. Sussman D.O., Kraus S.R., Carlsson M. et al. Onset of efficacy of tolterodine extendedrelease in patients with overactive bladder. Curr.Med. Res. Opin. 2007; 23:777-781.
  24. Hong W.S., Chung H., Lee J.M. et al. Polypharmacy and central nervous system adverse effects of anticholinergic agents in the men with benign prostatic hyperplasia. J Korean Continence Soc 2007; 11:24-29.
  25. Guidelines EAU, 2013.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies